Citizens reiterates TuHURA Biosciences stock rating on pipeline progress

Citizens has reissued an optimistic Market Outperform rating and a $9.00 price target for TuHURA Biosciences (NASDAQ:HURA), citing significant progress in the company's pipeline. The stock has already experienced a remarkable 200% increase year-to-date and has delivered a 103% return over the past six months, according to InvestingPro analysis.

TuHURA is concentrating on groundbreaking myeloid biology approaches and a late-stage product in development. The company's IFx-2.0 is currently undergoing FDA discussions for potential market approval, possibly bypassing a confirmatory study due to positive Phase 3 Progressive Overall Survival (PFS) data. TuHURA's next-generation assets concentrate on a novel method to treat Acute Myeloid Leukemia (AML) by targeting an immunosuppressive phenotype and repurposing the tumor microenvironment.

The company's TBS-2025 is scheduled for evaluation in mutant NPM1 r/r AML in a proof-of-concept study, with preclinical in vivo data expected in the second half of 2026. Additionally, TuHURA has submitted an IND application to the FDA for its TBS-2025 VISTA inhibiting antibody, targeting specific acute myeloid leukemia and blood cancer subsets.

This filing follows FDA guidance that no meeting is required and that the agency will issue written responses to the proposed Phase 1b/2 development plan.